11α-Hydroxyprogesterone

Not to be confused with 17α-hydroxyprogesterone.
11α-Hydroxyprogesterone
Clinical data
Other names11α-OHP; 11α-Hydroxypregn-4-ene-3,20-dione; 4-Pregnen-11α-ol-3,20-dione; δ4-Pregnen-11α-ol-3,20-dione
Identifiers
  • (8S,9S,10R,11R,13S,14S,17S)-17-acetyl-11-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
ECHA InfoCard100.001.189 Edit this at Wikidata
Chemical and physical data
FormulaC21H30O3
Molar mass330.468 g·mol−1
3D model (JSmol)
  • CC(=O)C1CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C
  • InChI=1S/C21H30O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h10,15-19,24H,4-9,11H2,1-3H3/t15-,16+,17-,18+,19+,20-,21+/m0/s1
  • Key:BFZHCUBIASXHPK-QJSKAATBSA-N

11α-Hydroxyprogesterone (11α-OHP), or 11α-hydroxypregn-4-ene-3,20-dione is an endogenous steroid and metabolite of progesterone.[1][2][3] It is a weak antiandrogen, and is devoid of androgenic, estrogenic, and progestogenic activity.[4][5][6]

11α-OHP was investigated as a topical antiandrogen for the treatment of androgen-dependent skin conditions in the early 1950s, and was found to produce some benefit.[7] In 1995, 11α-OHP, along with its epimer 11β-hydroxyprogesterone, was identified as a very potent competitive inhibitor of both isoforms (1 and 2) of 11β-hydroxysteroid dehydrogenase (11β-HSD).[2][3] It is notably not metabolized by 11β-HSD2.[8]

11α-OHP is a more potent inhibitor of 11β-HSD than enoxolone (glycyrrhetinic acid) or carbenoxolone in vitro (IC50 = 0.9 nM; IC50 = 5 nM in transfected cells).[8][9][10] The compound has been found to be highly active in conferring mineralocorticoid sodium-retaining activity of corticosterone in vivo in rat bioassays and in increasing blood pressure, effects that it mediates by preventing the 11β-HSD-mediated inactivation of endogenous corticosteroids.[2][3]

Because of its inhibition of 11β-HSD and consequent potentiation of corticosteroids, 11α-OHP has recently been patented for the treatment of skin diseases, particularly psoriasis in combination with clobetasol propionate and minoxidil.[5]

11α-OHP is used as a precursor in chemical syntheses of cortisone and hydrocortisone.[11][12][13]

See also[edit]

References[edit]

  1. ^ Ford DH (October 1954). "Effect of 11 alpha-hydroxyprogesterone on reproductive system of normal and pregnant adult wistar rats". The Journal of Clinical Endocrinology and Metabolism. 14 (10): 1268–1270. doi:10.1210/jcem-14-10-1268. PMID 13201630.
  2. ^ a b c Souness GW, Latif SA, Laurenzo JL, Morris DJ (April 1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat". Endocrinology. 136 (4): 1809–1812. doi:10.1210/endo.136.4.7895695. PMID 7895695.
  3. ^ a b c Souness GW, Morris DJ (March 1996). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat". Hypertension. 27 (3 Pt 1): 421–425. doi:10.1161/01.hyp.27.3.421. PMID 8698448.
  4. ^ Lerner LJ (1975). "Androgen antagonists". Pharmacology & Therapeutics B. 1 (2): 217–231. doi:10.1016/0306-039X(75)90006-9. PMID 772705. 11α Hydroxyprogesterone, while devoid of androgenic, estrogenic and progestational activity, is weakly anti androgenic in castrate rats.
  5. ^ a b Nguyen KT, Virus C, Günnewich N, Hannemann F, Bernhardt R (May 2012). "Changing the regioselectivity of a P450 from C15 to C11 hydroxylation of progesterone". ChemBioChem. 13 (8): 1161–1166. doi:10.1002/cbic.201100811. PMID 22532270. S2CID 34483686. 11α-Hydroxyprogesterone is an important pharmaceutical compound with anti-androgenic and blood-pressure-regulating activity. [...] 11α-Hydroxyprogesterone can therefore influence blood pressure regulation.12 Furthermore, 11α-hydroxyprogesterone exhibits an anti-androgenic activity with minimal estrogenic and progestational side effects.13 This substance was also recently patented for its role in treating skin diseases, especially for psoriasis in combination with clobetasol propionate and minoxidil.14.
  6. ^ Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacology & Therapeutics. 24 (3): 367–400. doi:10.1016/0163-7258(84)90010-X. PMID 6205409.
  7. ^ Millikan LE (19 April 2016). Drug Therapy in Dermatology. CRC Press. p. 403. ISBN 978-0-203-90831-0. Topical antiandrogens have also been tried, including topical progesterone, which proved ineffective. However, small studies with topical 11α-hydroxyprogesterone and 17α-estradiol showed some benefit [38,39].
  8. ^ a b Morita H, Zhou M, Foecking MF, Gomez-Sanchez EP, Cozza EN, Gomez-Sanchez CE (June 1996). "11 beta-Hydroxysteroid dehydrogenase type 2 complementary deoxyribonucleic acid stably transfected into Chinese hamster ovary cells: specific inhibition by 11 alpha-hydroxyprogesterone". Endocrinology. 137 (6): 2308–2314. doi:10.1210/endo.137.6.8641180. PMID 8641180. 11 alpha-Hydroxyprogesterone (11 alpha OH-P) was an order of magnitude more potent a competitive inhibitor of the 11 beta HSD-2 than was glycyrrhetinic acid (GA) (approximate IC50 = 0.9 vs. 15 nM).
  9. ^ Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, et al. (October 2004). "11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response". Endocrine Reviews. 25 (5): 831–866. doi:10.1210/er.2003-0031. PMID 15466942. In intact cells 11α-hydroxyprogesterone is a more potent inhibitor of 11β-HSD1 than glycyrrhetinic acid or 11β-hydroxyprogesterone (117, 118).
  10. ^ Bujalska I, Shimojo M, Howie A, Stewart PM (January 1997). "Human 11 beta-hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue". Steroids. 62 (1): 77–82. doi:10.1016/S0039-128X(96)00163-8. PMID 9029719. S2CID 22551136.
  11. ^ Dunn PJ, Wells A, Williams MT (2 February 2010). Green Chemistry in the Pharmaceutical Industry. John Wiley & Sons. pp. 2–. ISBN 978-3-527-62969-5.
  12. ^ Lamberth C, Dinges J (17 May 2016). Bioactive Carboxylic Compound Classes: Pharmaceuticals and Agrochemicals. Wiley. pp. 250–. ISBN 978-3-527-69396-2.
  13. ^ Ramawat KG, Mérillon JM (16 October 2008). Bioactive Molecules and Medicinal Plants. Springer Science & Business Media. pp. 5–. ISBN 978-3-540-74603-4.
Stub icon

This article about a steroid is a stub. You can help Wikipedia by expanding it.

Stub icon

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=11α-Hydroxyprogesterone&oldid=1166665758"